Dengue Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Dengue Treatment Market by Drug Class (NSAIDS, Antibiotics, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Dengue Treatment Market size was valued at 635.68 Million in 2021 and is estimated to reach 3117.07 Million by 2028, at a CAGR of 25.5% during the forecast period 2022 to 2028. Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue hemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications. Dengue Treatment market is expected to grow at a significant rate during forecast period. According to World Health Organization (WHO) estimates, 50 to 100 Mn infections occur annually, including 500,000 DHF cases and 22,000 deaths, mostly among children. Dengue treatment market is at developing stage. Market players collaborating to other companies or research institutions for the development of drugs for treating the dengue. For instance, in August 2013, Johnson and Johnson Services Inc. collaborated with biotechnology nonprofit organization The Wellcome Trust, for the development of prevention and treatment therapies for dengue fever.

Dengue Treatment Market

MARKET SUMMARY
-
25.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 25.5%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Dengue Treatment Market

  • Global dengue treatment market report gives comprehensive outlook on dengue treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global dengue treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, distribution channel and region.
  • This report studies global dengue treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market.
  • Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global dengue treatment products
Market Key Players
  • Roche AG
  • Sun Pharmaceutical Industries Limited
  • Abbivax
  • Takeda Pharmaceutical Company
  • Merck & Co Inc.
  • VABIOTECH
Market Dynamics

Dengue Treatment Market

Global dengue treatment market anticipated surging its growth owing to rise in dengue burden in tropical and sub-tropical regions, increased government funding to fight against dengue, and unmet market needs of managing dengue burden around the world. In addition, market players keen interest in uplift the market by partnerships, promising dengue pipelines and rise in medical insurance in developing countries is anticipated to drive the market furthermore. However, lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and the high-cost of treatment are hindering the dengue-treatment market.


North-America Got Significant Share

Dengue Treatment Market

North America leads due to the presence of the world's largest consumer market with a high GDP, as well as a growing focus on increasing R&D operations in the pharmaceutical and biotech industries and increasing outsourcing services. The Asia-Pacific region is predicted to grow at the fastest CAGR during the forecast period, as the demand for dengue treatment products in Asia-Pacific countries is quickly increasing due to urbanisation and laboratory automation. As one of the main countries inculcating dengue treatment, China is likely to dominate the Asia-Pacific dengue treatment market. Due to increased R&D activity in the pharma and biotech sectors, Europe is predicted to develop at a CAGR throughout the forecasted period. Germany is anticipated to be the market leader in Europe.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In September 2017, Abbivax and Evotec AG entered into strategic partnership to develop novel antiviral agents including dengue virus, influenza and others.

Key

Key Features of the Report

Dengue Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Roche AG
  • Sun Pharmaceutical Industries Limited
  • Abbivax
  • Takeda Pharmaceutical Company
  • Merck & Co Inc.
  • VABIOTECH

Description

Dengue Treatment Market size was valued at 635.68 Million in 2021 and is estimated to reach 3117.07 Million by 2028, at a CAGR of 25.5% during the forecast period 2022 to 2028. Dengue fever is also known as break bone fever is mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several species of mosquitos of the Aedes type, principally A. aegypti. Symptoms of dengue include fever, headache vomiting, muscle and joint pains, and characteristic skin rash. On infection of dengue, patient will automatically recover within seven days. But in some cases, it may develop to life threatening dengue hemorrhagic fever. The virus has five different types of strains, infection with one strain usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications. Dengue Treatment market is expected to grow at a significant rate during forecast period. According to World Health Organization (WHO) estimates, 50 to 100 Mn infections occur annually, including 500,000 DHF cases and 22,000 deaths, mostly among children. Dengue treatment market is at developing stage. Market players collaborating to other companies or research institutions for the development of drugs for treating the dengue. For instance, in August 2013, Johnson and Johnson Services Inc. collaborated with biotechnology nonprofit organization The Wellcome Trust, for the development of prevention and treatment therapies for dengue fever.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX